35382-88-8 Usage
Description
N-(Benzoylphenyl)-2,2,2-trichloroacetamide is an organic compound that serves as a crucial reagent in the pharmaceutical industry. It is characterized by its unique molecular structure, which features a benzoylphenyl group attached to a trichloroacetamide moiety. N-(Benzoylphenyl)-2,2,2-trichloroacetaMide plays a significant role in the synthesis of various pharmaceutical agents, making it an essential component in drug development.
Uses
Used in Pharmaceutical Industry:
N-(Benzoylphenyl)-2,2,2-trichloroacetamide is used as a reagent for the preparation of pharmaceuticals. Its unique chemical properties and structure make it a valuable component in the synthesis of various drugs, contributing to the development of new and improved medications.
Used in the Synthesis of Afacifenacin (A355005):
N-(Benzoylphenyl)-2,2,2-trichloroacetamide is specifically utilized in the synthesis of Afacifenacin (A355005), a stereoisomer of afacifenacin (A355000). Afacifenacin functions as a sodium/calcium exchanger inhibitor, which is instrumental in the prevention of reperfusion injury. This injury is commonly associated with the restoration of coronary blood flow via surgery, making N-(Benzoylphenyl)-2,2,2-trichloroacetamide an essential component in the development of this life-saving medication.
Check Digit Verification of cas no
The CAS Registry Mumber 35382-88-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,3,8 and 2 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 35382-88:
(7*3)+(6*5)+(5*3)+(4*8)+(3*2)+(2*8)+(1*8)=128
128 % 10 = 8
So 35382-88-8 is a valid CAS Registry Number.
35382-88-8Relevant articles and documents
A novel class of sodium/calcium exchanger inhibitor: Design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives
Hasegawa, Hirohiko,Muraoka, Masami,Ohmori, Mikiko,Matsui, Kazuki,Kojima, Atsuyuki
, p. 3721 - 3735 (2007/10/03)
Design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives as inhibitors of the sodium/calcium (Na+/Ca2+) exchanger are discussed. These studies, based on a lead compound 9a, which was identified in our library, involved systematic modification of three regions and revealed that (1) the 3,4-dihydro-2(1H)- quinazolinone having a tertiary amino alkyl side chain at the 3-position is essential for activity, (2) a nonsubstituted phenyl ring is most suitable for high activity, and (3) introduction of a 4-substituted piperidine moiety enhanced the activity, in particular 4-benzylpiperidin-1-yl showed strong inhibitory activity. Based on these SAR studies, a structurally novel and highly potent inhibitor against the Na+/Ca2+ exchanger, 12g (SM-15811), was discovered. In particular, SM-15811 directly inhibited the Na+-dependent Ca2+ influx via the Na+/Ca 2+ exchanger in cardiomyocytes with a high potency. The activity was almost two orders more potent than the lead compound 9a and SM-15811 exerted a protective effect against myocardial ischemic reperfusion injury. These Na +/Ca2+ inhibitors could have a therapeutic potential for the treatment of ischemic reperfusion injury.
Synthesis and pharmacological evaluation of 1,4-dihydro-2H-3,1-benzoxazin-2-one derivatives.
De Marchi,Tamagnone,Torielli
, p. 1757 - 1759 (2007/10/09)
-